



Leadership team and clinical advisory network strengthened

- **Matthew Dodds appointed Chief Financial Officer, bringing over 30 years of healthcare, medical technology, capital markets, corporate development and investor relations experience**
- **He is a former senior executive at LivaNova PLC and Johnson & Johnson Medical Devices, with more than two decades as a top-ranked Wall Street medical technology analyst**
- **Dr Vinod Thourani appointed Clinical Advisor, adding one of the world's leading structural heart and valve disease specialists to Echo IQ's growing network of key opinion leaders**
- **Dr Thourani currently serves as Chairman of Cardiovascular Surgery at Piedmont Healthcare and Surgical Director of the Piedmont Heart Institute Structural Center of Excellence in Atlanta, Georgia**
- **Piedmont Healthcare is recognised as a leading US cardiovascular care network and a major adopter of structural heart and valve therapies**
- **Appointment provides Dr Thourani with direct insight into the clinical workflows and patient populations targeted by Echo IQ's AI-powered diagnostic solutions**
- **Dr Thourani further strengthens Echo IQ's clinical leadership alongside internationally recognised cardiovascular specialists including Dr Philippe Genereux**
- **Strategic appointments support Echo IQ's next phase of commercial growth, FDA initiatives and expanding engagement with leading US cardiovascular institutions**

Sydney: Artificial Intelligence (“AI”) and Medical Technology Company Echo IQ Limited (ASX: EIQ) (“Echo IQ” or “the Company”) is pleased to announce the appointment of Matthew Dodds as Chief Financial Officer effective 24 June 2026 and Dr Vinod Thourani as Clinical Advisor.

The appointments further strengthen Echo IQ's executive leadership team and broader clinical advisory network as the Company continues to advance commercialisation of its EchoSolv platform and expand its presence within the US healthcare market.

Mr Dodds joins Echo IQ with more than 30 years of experience across healthcare, medical technology, capital markets, corporate development, strategy, investor relations, business development and public company leadership.

Most recently, he served as Senior Vice President, Corporate Development & IT at LivaNova PLC, where he was a member of the executive leadership team and held responsibility for corporate development, investor relations, corporate communications, enterprise IT and strategic initiatives. Prior to LivaNova, Mr Dodds served as Vice President, Strategic Planning for Johnson & Johnson Medical Devices, helping lead strategic planning, business development and investor relations initiatives across one of the world's largest medical technology businesses.

Earlier in his career, Mr Dodds spent more than two decades on Wall Street as a leading medical technology equity research analyst, including serving as Americas Sector Head of Healthcare Equity Research at Citigroup. During this period, he advised institutional investors on many of the world's largest healthcare and medical device companies, developing extensive relationships across the global healthcare investment community.

In parallel, Echo IQ is pleased to announce the appointment of Dr Vinod Thourani as Clinical Advisor.

Dr Thourani is internationally recognised as one of the foremost authorities in structural heart disease, heart valve therapies and cardiovascular surgery. He currently serves as the Bernie Marcus Chairman of the Department of Cardiovascular Surgery at Piedmont Healthcare and the Marcus Heart and Vascular and Valve Center of the



Piedmont Heart Institute in Atlanta, Georgia, where he also serves as Surgical Director of the Structural Center of Excellence.

Dr Thourani has held numerous leadership positions across the global cardiovascular community, including Past President of the Heart Valve Society, Past President of the Southern Thoracic Surgical Association and Past President of the South Atlantic Cardiovascular Society. He currently serves on the Board of Directors of the Society of Thoracic Surgeons and is Treasurer of the organisation, while also holding leadership positions with the International Society of Minimally Invasive Cardiothoracic Surgery, the American College of Cardiology and multiple international cardiovascular organisations.

He has authored more than 620 peer-reviewed publications and serves as Principal Investigator or Steering Committee member across numerous landmark structural heart and valve disease clinical trials. Dr Thourani is widely regarded as one of the leading clinical voices in the diagnosis and treatment of structural heart disease and valvular disorders globally.

The appointment further expands Echo IQ's network of leading cardiovascular Key Opinion Leaders and complements the Company's existing relationships with internationally recognised clinicians including Dr Philippe Genereux, reinforcing Echo IQ's position at the forefront of AI-enabled cardiovascular diagnostics.

Management commentary:

Chief Executive Officer, Mr Dustin Haines said: *"These appointments significantly strengthen both the commercial and clinical foundations of Echo IQ as we continue executing our growth strategy in the United States.*

Matthew brings a rare combination of healthcare operating experience, strategic leadership, capital markets expertise and investor engagement capability. His experience across Wall Street, Johnson & Johnson and LivaNova provides Echo IQ with an executive who understands not only how to build and scale medical technology businesses, but also how to effectively communicate value to high profile US investors and strategic partners. As we continue expanding our commercial footprint and evaluating strategic opportunities into the US healthcare sector and more broadly, Matthew's experience will be invaluable.

We are equally excited to welcome Dr Vinod Thourani as a Clinical Advisor. Vinod is widely regarded as one of the world's leading experts in structural heart disease and valve therapies, with an exceptional reputation across both the clinical and academic cardiovascular communities. His appointment further strengthens our already impressive network of Key Opinion Leaders and reflects the growing interest from leading cardiovascular specialists in the role artificial intelligence can play in improving disease detection and patient outcomes.

Together, these appointments further position Echo IQ to accelerate commercial adoption, deepen engagement with leading healthcare institutions and continue building a world-class cardiovascular AI platform."

Chief Financial Officer, Mr Matthew Dodds added: *"I am excited to join Echo IQ at an important stage in the Company's evolution. Echo IQ has built a differentiated platform addressing major unmet needs in cardiovascular care and sits at the intersection of artificial intelligence, clinical workflow and scalable healthcare technology. I look forward to working with Dustin, the Board and the broader team to help build the financial, strategic and commercial infrastructure required for the Company's next phase of growth."*

The Company will issue a total of 6,000,000 unlisted options to incoming team members on appointment. The options will have an exercise price equal to the 30-day Volume Weighted Average Price (VWAP) of the Company's shares trading on the ASX and a 3-year expiry period. An appendix 3G will be released to the market following issuance.

- ENDS -



Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations
Henry.jordan@sdir.com.au / +61 (0) 431 271 538

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.
The company is based in Sydney, Australia.

For personal use only